Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$TWTR Twitter: Tapped Out Or Just Getting Going? Deutsche Bank Thinks The Latter http://www.smarteranalyst.com/2014/10/07/twitter-tapped-just-getting-going-deutsche-bank-thinks-latter/
$FATE H.C. Wainwright Reiterates Buy On Fate Therapeutics Following Meeting With Management http://www.smarteranalyst.com/2014/10/07/h-c-wainwright-reiterates-buy-fate-therapeutics-following-meeting-management/
$OMER Maxim Maintains Buy On Omeros Following New Commercial Supply Agreement http://www.smarteranalyst.com/2014/10/07/maxim-group-maintains-buy-omeros-following-new-commercial-supply-agreement/
$OMER Maxim Maintains Buy On Omeros Following New Commercial Supply Agreement http://www.smarteranalyst.com/2014/10/07/maxim-group-maintains-buy-omeros-following-new-commercial-supply-agreement/
$ISR Maxim Reiterates Buy On IsoRay As Its Brain Tumor Seed Shows Positive Results http://www.smarteranalyst.com/2014/10/07/maxim-reiterates-buy-isoray-brain-tumor-seed-shows-positive-results/
$ISR Maxim Reiterates Buy On IsoRay As Its Brain Tumor Seed Shows Positive Results http://www.smarteranalyst.com/2014/10/07/maxim-reiterates-buy-isoray-brain-tumor-seed-shows-positive-results/
$STEM Maxim Group Reiterates Buy On StemCells Following Initiation Of Pathway Study http://www.smarteranalyst.com/2014/10/07/maxim-group-reiterates-buy-stemcells-following-initiation-pathway-study/
$REGN Roth Capital Maintains Buy On Regeneron Following Eylea FDA Approval http://www.smarteranalyst.com/2014/10/07/roth-capital-maintains-buy-regeneron-following-eylea-fda-approval/
$REGN Roth Capital Maintains Buy On Regeneron Following Eylea FDA Approval http://www.smarteranalyst.com/2014/10/07/roth-capital-maintains-buy-regeneron-following-eylea-fda-approval/
$DRTX Durata To Be Acquired by Actavis; We View The Cash Bid As Reasonable, Says Roth Capital http://www.smarteranalyst.com/2014/10/07/durata-acquired-actavis-view-cash-bid-reasonable-says-roth-capital/
$ADHD Alcobra: While The Stock Is Under Pressure Our Long-Term Thesis Remains Intact, Says Roth Capital http://www.smarteranalyst.com/2014/10/07/alcobra-stock-pressure-long-term-thesis-remains-intact-says-roth-capital/
$ADHD Alcobra: While The Stock Is Under Pressure Our Long-Term Thesis Remains Intact, Says Roth Capital http://www.smarteranalyst.com/2014/10/07/alcobra-stock-pressure-long-term-thesis-remains-intact-says-roth-capital/
$SNSS Sunesis: Investors Should Now Remain On The Sidelines, Says Roth Capital http://www.smarteranalyst.com/2014/10/07/sunesis-investors-should-now-remain-on-the-sidelines-says-roth-capital/
$SNSS Sunesis: Investors Should Now Remain On The Sidelines, Says Roth Capital http://www.smarteranalyst.com/2014/10/07/sunesis-investors-should-now-remain-on-the-sidelines-says-roth-capital/
$TRIP Deutsche Bank Analyzes TripAdvisor’s Instant Book Footprint; Reiterates Buy http://www.smarteranalyst.com/2014/10/06/deutsche-bank-analyzes-tripadvisors-instant-book-footprint-reiterates-buy/
$PTCT PTC Therapeutics: EU Translarna Launch May Generate Headwinds, Says Cowen http://www.smarteranalyst.com/2014/10/06/ptc-therapeutics-eu-translarna-launch-may-generate-headwinds-says-cowen/
PTC Therapeutics: EU Translarna Launch May Generate Headwinds, Says Cowen http://www.smarteranalyst.com/2014/10/06/ptc-therapeutics-eu-translarna-launch-may-generate-headwinds-says-cowen/
$SNSS Sunesis: Despite Primary Endpoint Miss Vosaroxin Still Holds Value, Says Cowen http://www.smarteranalyst.com/2014/10/06/sunesis-despite-primary-endpoint-miss-vosaroxin-still-holds-value-says-cowen/
$SNSS Sunesis: Despite Primary Endpoint Miss Vosaroxin Still Holds Value, Says Cowen http://www.smarteranalyst.com/2014/10/06/sunesis-despite-primary-endpoint-miss-vosaroxin-still-holds-value-says-cowen/
$RMTI Brean Capital Remains Bearish On Rockwell Medical, Sees 62% Downside http://www.smarteranalyst.com/2014/10/06/brean-capital-remains-bearish-rockwell-medical-sees-62-downside/
$RMTI Brean Capital Remains Bearish On Rockwell Medical, Sees 62% Downside http://www.smarteranalyst.com/2014/10/06/brean-capital-remains-bearish-rockwell-medical-sees-62-downside/
$BA Oppenheimer Maintains Perform On Boeing Following 3Q14 Commercial Deliveries Update http://www.smarteranalyst.com/2014/10/06/oppenheimer-maintains-perform-boeing-following-3q14-commercial-deliveries-update/
$MDT Oppenheimer Maintains Outperform On Medtronic On The Back Of Financial Plans http://www.smarteranalyst.com/2014/10/06/oppenheimer-maintains-outperform-medtronic-back-financial-plans/
$SCTY SolarCity: The Shares At Current Levels Represent An Attractive Entry Point, Says Roth Capital http://www.smarteranalyst.com/2014/10/06/solarcity-shares-current-levels-represent-attractive-entry-point-says-roth-capital/
$SCTY SolarCity: The Shares At Current Levels Represent An Attractive Entry Point, Says Roth Capital http://www.smarteranalyst.com/2014/10/06/solarcity-shares-current-levels-represent-attractive-entry-point-says-roth-capital/
$IAG Roth Capital Slightly Raises IAMGOLD Price Target To $5.50; Maintains Buy http://www.smarteranalyst.com/2014/10/06/roth-capital-slightly-raises-iamgold-price-target-5-50-maintains-buy/
$IAG Roth Capital Slightly Raises IAMGOLD Price Target To $5.50; Maintains Buy http://www.smarteranalyst.com/2014/10/06/roth-capital-slightly-raises-iamgold-price-target-5-50-maintains-buy/
$JAZZ $FLML Canaccord Provides Input Into Jazz’s Patent Fight Against Flamel On Xyrem http://www.smarteranalyst.com/2014/10/03/canaccord-provides-input-jazzs-patent-fight-flamel-xyrem/
$JAZZ $FLML Canaccord Provides Input Into Jazz’s Patent Fight Against Flamel On Xyrem http://www.smarteranalyst.com/2014/10/03/canaccord-provides-input-jazzs-patent-fight-flamel-xyrem/
$CERS Cerus: Ebola Outbreak Lowers FDA Risk Further, Says Wedbush http://www.smarteranalyst.com/2014/10/03/cerus-ebola-outbreak-lowers-fda-risk-says-wedbush/
$CERS Cerus: Ebola Outbreak Lowers FDA Risk Further, Says Wedbush http://www.smarteranalyst.com/2014/10/03/cerus-ebola-outbreak-lowers-fda-risk-says-wedbush/
$ULTA William Blair Comments On Ulta Following Investor Meetings With Management http://www.smarteranalyst.com/2014/10/03/william-blair-comments-ulta-beauty-following-investor-meetings-management/
$SLXP William Blair Maintains Outperform On Salix Following Cosmo Deal Cancellation http://www.smarteranalyst.com/2014/10/03/william-blair-maintains-outperform-salix-following-cosmo-deal-cancellation/
$KO UBS Remains Neutral On Coca-Cola Following New Equity Stewardship Guidelines http://www.smarteranalyst.com/2014/10/03/ubs-remains-neutral-coca-cola-following-new-equity-stewardship-guidelines/
$CERN Deutsche Bank Remains Positive On Cerner Following Positive Feedback On Siemens Deal From KLAS http://www.smarteranalyst.com/2014/10/03/deutsche-bank-remains-positive-cerner-following-positive-feedback-siemens-deal-klas/
$AAPL Apple’s Ability To Surprise From Here Seems Limited, Says Deutsche Bank http://www.smarteranalyst.com/2014/10/03/apples-ability-surprise-seems-limited-says-deutsche-bank/
$AAPL Apple’s Ability To Surprise From Here Seems Limited, Says Deutsche Bank http://www.smarteranalyst.com/2014/10/03/apples-ability-surprise-seems-limited-says-deutsche-bank/
$MASI Roth Capital Assigns Buy On Masimo Following Patent Victory http://www.smarteranalyst.com/2014/10/03/roth-capital-assigns-buy-masimo-following-patent-victory/
$CRIS Roth Capital Reiterated Buy On Curis On The Back Of Clinical Development Update http://www.smarteranalyst.com/2014/10/03/roth-capital-reiterated-buy-curis-back-clinical-development-update/
$ALIM Cowen Maintains Bullish Stance On Alimera On The Heels Of Iluvien FDA Approval http://www.smarteranalyst.com/2014/10/03/cowen-maintains-bullish-stance-alimera-heels-iluvien-fda-approval/